(Press-News.org) Cambridge, MA, Mar 13 — Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E financing led by a private equity fund of Value Partners Group (HKG:0806), one of Asia’s largest independent asset management firms, with strong participation from industry- and technology-focused new investors, as well as continued support from global existing backers.
The funds raised in this round will be directed to advance Insilico's innovative drug pipeline and AI platform developments. On one side, resources will focus on refining AI models and algorithms, alongside updates and expansions to its state-of-the-art robotics lab to further automate and streamline R&D processes. On the other side, Insilico will focus on advancing the clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment and accelerating the exploration of other independently developed and co-developed drug pipelines, driving impactful innovations in healthcare.
“We are excited to partner with Insilico Medicine in its mission to transform drug discovery with AI and automation. With a proven track record and a leadership position in AI-driven drug development, Insilico is at the forefront of transforming the industry. We believe that Insilico’s advancements will not only accelerate the development of life-saving therapies but also redefine the future of biopharmaceutical R&D. This partnership also marks a significant milestone for Value Partners’ private equity strategy and our vision of investing in disruptive innovations that have the potential to reshape industries.” said Dr. Chuen Yan Leung, Partner (Healthcare Investments)
"We are thrilled to announce our $110 million Series E financing—a key milestone that reflects our unwavering commitment to transforming healthcare and the strong confidence of our investors. This round, led by Value Partners and anchored by industry-focused investors, was heavily oversubscribed, drawing exceptional interest from prominent investors,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "The funds raised will accelerate the advancement of our drug pipeline and AI platform, further solidifying Insilico’s leadership in this rapidly evolving sector. We remain dedicated to our mission of extending productive longevity to people and are proud to be at the forefront of innovation in healthcare."
Since its previous financing round, Insilico has achieved substantial progress in both the development of AI platform and drug discovery pipeline and has showcased the ability of its proprietary AI-driven platform to significantly reduce costs and enhance efficiency in the early stages of drug discovery. As its announced key benchmarks for internal preclinical candidate (PCC) programs show: By integrating advanced AI and automation technologies, Insilico has reduced the average time to PCC nomination to just 12-18 months compared to traditional drug discovery methods (typically require 2.5-4 years) , while enabling the synthesis and testing of only 60-200 molecules per program.
Pharma.AI, the proprietary platform developed by Insilico, undergoes major updates twice a year to maintain its technological edge. Built around generative AI and continuously integrating cutting-edge technologies, Pharma.AI provides a comprehensive solution spanning biology, generative chemistry, clinical medicine, and scientific research. As the technology evolves, Insilico has further enhanced Pharma.AI by introducing innovative engines powered by large language models (LLMs), including Nach01, a multimodal foundation model for natural and chemical languages, and Dora, a multi-agent generative research assistant. Recently, Insilico deployed the first bipedal humanoid AI Scientist within Life Star1, its fully robotic lab connected to Pharma.AI, designed to further optimize and automate research workflows.
To date, Insilico has rapidly built a wholly-owned drug discovery portfolio of 30 assets driven by its advanced Pharma.AI platform, with 10 of these assets receiving IND clearance. Among them, the most advanced candidate, Rentosertib (formerly known as ISM001-055), developed for treating idiopathic pulmonary fibrosis (IPF), has progressed through multiple clinical studies with encouraging results. In a completed Phase IIa clinical trial, Rentosertib demonstrated favorable safety and tolerability across all dose levels, along with dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.
In addition, Insilico has established a sustainable revenue stream through its business model centered on out-licensing deals for its pipelines. The company has secured four pipeline out-licensing agreements with Fosun Pharma, Exelixis, and Menarini, collectively valued at over $2.1 billion. Concurrently, Insilico has initiated multiple drug discovery and development collaborations with industry partners, including Sanofi, Saudi Aramco, Therasid Bioscience and others, with the collected value of over $1.4 billion. Many of these partnerships have reached milestones, resulting in milestone payments to Insilico, further contributing to the company's growing financial performance.
With the successful completion of its Series E financing, Insilico will further accelerate the advancement of AI-powered biopharmaceutical research and development, strengthen collaboration across the industry value chain, and drive the application of its cutting-edge AI platform in diverse scenarios within the life sciences sector through flagship use cases.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
For more information, please visit www.insilico.com.
About Value Partners Group Limited
Value Partners, one of Asia's leading independent asset management firms, seeks to offer world-class investment services and products. Since its establishment in 1993, the Company has been a dedicated, specialist value investor in Greater China and Asia. In November 2007, Value Partners Group became the first asset management firm to be listed on the Main Board of the Hong Kong Stock Exchange (Stock code: 806 HK). In addition to its Hong Kong headquarters, the firm operates in Shanghai, Shenzhen, Singapore and London. Value Partners' investment strategies cover equities, fixed income, multi-asset, alternatives, real estate and quantitative investment solutions, for institutional and individual clients in Asia Pacific, Europe and the United States.
For more information, please visit www.valuepartners-group.com.
END
Insilico Medicine secures $110 million Series E financing to advance AI and robotics- driven drug discovery innovation
2025-03-13
ELSE PRESS RELEASES FROM THIS DATE:
Researchers at Case Western Reserve University identify RNA molecule as possible driver of gastric cancer
2025-03-13
CLEVELAND—Researchers at Case Western Reserve University have discovered molecules that present the potential to drive the development of gastric cancer—among the world’s deadliest forms of the disease.
Gastric, or stomach cancer, remains one of the leading causes of cancer-related deaths, according to the American Cancer Society, because it’s difficult to diagnose at an early stage and treatments often fail once the disease has spread.
But a team of researchers led by Kishore Guda, associate professor at the Digestive ...
ENDO 2025 opens media registration
2025-03-13
WASHINGTON—Members of the media can now register to cover hormone health and science advances at ENDO 2025, the Endocrine Society’s annual meeting. The meeting will take place July 12-15, in San Francisco, Calif.
ENDO 2025 offers journalists the opportunity to discuss groundbreaking research with world-renowned experts in diverse fields, including obesity, diabetes, reproductive health, endocrine-disrupting chemicals, bone health and thyroid cancer. The meeting is the premier global conference in endocrinology research and clinical care. The event is expected to draw thousands of people from all over the world.
This year’s program will feature ...
Study: ‘Sustainable intensification’ on the farm reduces soil nitrate losses, maintains crop yields
2025-03-13
CHAMPAIGN, Ill. — A nine-year study comparing a typical two-year corn and soybean rotation with a more intensive three-year rotation involving corn, cereal rye, soybean and winter wheat, found that the three-year system can dramatically reduce nitrogen — an important crop nutrient — in farm runoff without compromising yield.
The new findings are detailed in the journal Frontiers in Environmental Science.
“Subterranean drainage pipes called tiles transport nitrogen, in the form of nitrate, from fields to streams, impairing downstream surface waters,” the scientists wrote. ...
A closer look at severe tricuspid regurgitation in AFMR patients
2025-03-13
Atrial functional mitral regurgitation (AFMR) is a common type of MR linked to high rates of heart failure, highlighting the need to understand its prognostic factors. Tricuspid regurgitation (TR) is a known prognostic factor in heart diseases like heart failure and degenerative MR. It is also frequently observed in AFMR patients, making it crucial to understand its impact on AFMR outcomes.
To address this gap, a research team led by Dr. Tomohiro Kaneko and Dr. Nobuyuki Kagiyama from the Department of Cardiovascular Biology and Medicine at ...
Watching nature scenes can reduce pain, new study shows
2025-03-13
A new neuroimaging study has revealed that viewing nature can help ease how people experience pain, by reducing the brain activity linked to pain perception.
Published in the journal Nature Communications and led by a team from the University of Vienna and University of Exeter, the research offers a promising foundation for new types of non-pharmacological pain treatments.
Using an fMRI scanner, researchers monitored the brain activity of 49 participants in Austria, as they received pain delivered through a series of small electric shocks. When they were watching videos of a natural scene compared to ...
Scientists from IOCB Prague are on track of finding a treatment for autoimmune hair loss
2025-03-13
A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and Louis Garza at Johns Hopkins University, have developed a compound that could potentially treat the autoimmune disorder alopecia areata, which causes hair loss leading to the formation of bald patches.The results of their study, recently published in the Journal of Medicinal Chemistry, confirm the efficacy of a series of prodrugs based on derivatives of itaconic acid, simply referred to as itaconates. What is more, there is a good chance that the substances will be ...
Literary theorist Gayatri Chakravorty Spivak named 2025 Holberg Prize Laureate
2025-03-13
(BERGEN, Norway) – Today, the Holberg Prize—one of the largest international prizes awarded annually to an outstanding researcher in the humanities, social sciences, law or theology—named Indian scholar Gayatri Chakravorty Spivak as its 2025 Laureate.
Spivak is University Professor in the Humanities at Columbia University. She will receive the award of NOK 6,000,000 (approx. EUR 515,000) during a 5th June ceremony at the University of Bergen, Norway.
Spivak is considered one of the most influential global intellectuals of our time, and she has shaped literary criticism and philosophy since the ...
The relationship between gut microbiota, immunoglobulin A, and vaccine efficacy
2025-03-13
Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause various diseases, such as pneumonia. This conclusion is drawn from a recent study led by the B Cell Biology Research Group at the Hospital del Mar Research Institute, published in Science Advances.
Researchers analyzed vaccine responses using genetically modified mouse models to study two types of pneumococcal vaccines-one commonly used in children and another in adults. Although these vaccines function through different mechanisms, both provide broad coverage. However, in individuals with a specific type of immunodeficiency, immunoglobulin ...
Advancing sorghum science: drought-resilient crop for Spain's agricultural future
2025-03-13
Press release
Information embargoed until March 13, 2025, at 09:00 am (time in Barcelona, Spain)
Sorghum is an increasingly important crop for animal and human nutrition, especially in arid and semi-arid regions, due to its natural resistance to drought and high temperatures.
CRAG researchers have identified the molecular mechanisms responsible for drought resistance in sorghum and developed tools that could be used in biotechnological applications.
These advances could combat the effects of climate change, reduce dependence on imports and improve food security for human consumption.
Bellaterra (Barcelona), 13 March ...
Round up, just below, or precise amount? Choosing the final price of a product may be just a cultural thing
2025-03-13
It is well known that culture influences consumer behavior, but the impact of culture on pricing is less studied. One way culture might reflect in price tags is through price endings, which can be round (eg $10.00), just below (eg £9.99), or precise (eg €9.87). While all these price endings are common, little is known about why sellers in certain markets prefer one over the others.
Now, researchers in Germany have examined whether cultural dimensions – individualism, uncertainty avoidance, and long-term orientation – impact how often consumers see certain types of price endings.
“Given that culture significantly influences behavior, cognition, ...